May 13, 2020
BioPharmX Corporation Announces Approval of Merger by Stockholders at Special Meeting
May 08, 2020
BioPharmX Corporation Urges Stockholders to Vote Now on Proposed Merger with Timber Pharmaceuticals
Apr 27, 2020
BioPharmX Corporation Announces that its Special Stockholders' Meeting will now be held on Wednesday, May 13, 2020 at 10:00 AM eastern time
Mar 25, 2020
BioPharmX Receives Notice of Delisting from NYSE American But Stock will Remain Trading
Jan 28, 2020
BioPharmX And Timber Pharmaceuticals Announce Entry into Merger Agreement
Dec 10, 2019
BioPharmX Reports Fiscal Third Quarter 2020 Financial Results and Provides Corporate Update
Sep 20, 2019
BioPharmX Receives Notice of Compliance Deadline Extension from NYSE American
Jul 16, 2019
BioPharmX Announces Steven M. Bosacki Joins the Company as Chief Operating Officer
Jun 25, 2019
BioPharmX Announces Positive Topline Results from Phase 2b Trial of BPX-04 for Papulopustular Rosacea
Jun 11, 2019
BioPharmX Reports Fiscal First Quarter 2020 Financial Results
May 22, 2019
BioPharmX Announces Last Patient Visit in Phase 2b Trial of BPX-04 for Papulopustular Rosacea
Apr 26, 2019
BioPharmX Completes 1-for-25 Reverse Stock Split
Apr 15, 2019
BioPharmX Announces Reverse Stock Split
Mar 21, 2019
BioPharmX Announces $3.9 Million Offering
Mar 18, 2019
BioPharmX to Participate in the 31st Annual ROTH Conference and the Oppenheimer 29th Annual Healthcare Conference
Mar 04, 2019
BioPharmX Completes Enrollment in Phase 2b Trial of BPX-04 for Patients with Papulopustular Rosacea
Feb 27, 2019
BioPharmX Receives Notice of Compliance Deadline Extension from NYSE American
Feb 04, 2019
BioPharmX Strengthens Board of Directors with Appointment of Industry Veteran Dr. R. Todd Plott
Dec 20, 2018
BioPharmX Receives Notice of Noncompliance from NYSE American
Dec 06, 2018
BioPharmX Reports Third Quarter 2019 Financial Results